Systematic reviews in cystic fibrosis
Rosalind L Smyth MD 30 years. In 1960 the estimated median survival for children born with CF was less than 5 years, whereas in 1990 it was 40 years1. In this time, the perception of CF by health care professionals, patients and the general public has changed from that of a lethal disorder, about which very little could be done, to that of a condition, where careful attention to appropriate treatment would ensure survival with an acceptable quality of life, well into adulthood. By the year 2000, it is expected that there will be over 3000 adults with the disease. Thereafter there will be more adults than paediatric patients. One of the consequences of these trends is the emergence of a very articulate body of patients and parents. They are often more knowledgeable about CF than most doctors, are sharply focused on their own, or their child's limited future, and are powerful advocates for their perceived requirements of care. This collective demand for defined standards of care is a potentially commanding factor in the provider/purchaser system in the National Health Service.
Maintaining these standards of care is expensive. It was estimated in 1989/1990 , that the average annual cost of caring for a patient with CF was £82412. The cost of a patient receiving a high level of care was more than 20 times greater than that for the patient requiring minimal care. Medication accounted for 57% of the total costs. Other, expensive treatments have become available since then, for example nebulized DNA-ase3, which reduces the viscosity of sputum in CF patients, costs around £7500 per patient per annum. In the face of such pressure to maintain the trend towards improved survival, it It is generally accepted that the most efficient method to evaluate treatment, particularly where the effect is modest rather than large and instantly obvious, is the RCT. Unfortunately, RCTs do not always lead to a widely accepted treatment policy because, even if they are sound methodologically, they are frequently too small to provide a precise and, therefore, convincing result. Also one is often confronted by a number of RCTs which show a trend in favour, or against, a particular treatment and perhaps one or two trials which have a statistically significant but imprecise result because of inadequate sample size.
A major strength of RCTs is that the randomization should prevent bias in treatment allocation, but when reviewing a group of trials it is important to minimize bias in the studies that are selected for inclusion in the review. Such a review should be systematic, with clearly defined and reproducible methods, as for a primary research project. Indeed, it is increasingly recognized that rigorous scientific methodology is just as necessary for reviewing a number of RCTs, or any other source of evidence, as it is performing RCTs in the first place9. Such reviews have been termed systematic (also called scientific reviews) to distinguish them from more traditional reviews or overviews of topic areas conducted by experts in the field. Although they are widely read, the potential for bias in such overviews is high, as authors frequently start out from a particular viewpoint and may only quote references which support their predetermined opinion. Not only does a review of the evidence from all relevant RCTs provide an unbiased estimate of a treatment effect, but a much more precise estimate simply because the effective sample size is effective treatments from oblivion (e.g. thrombolysis for acute myocardial infarction10), but also consigned ineffective treatments to oblivion (e.g. lidocaine in acute myocardial infarction1l). Many lay people find it astounding that clinicians continue to recommend treatment strategies that have not been evaluated rigorously by such methods.
HOW TO CONDUCT A SYSTEMATIC REVIEW
Checklists for reviewers6 conducting a systematic review require, first, that the objectives of the review are clearly focused and, secondly, that the criteria used to select studies and to assess their validity should be explicit and consistent with the focus of the review (Figure 1 ). This second point is important, as the quality of information which may be obtained from a review depends on that of the studies included. To avoid bias, these criteria must be determined a priori and preferably blindly, i.e. without knowledge of details such as authors' names12.
It is important that all potentially relevant studies are identified. In Cochrane reviews this process is described in the protocol. The search strategy (for electronic databases) should therefore be sufficiently comprehensive, which means that it may not be very precise. It is also important to consider unpublished studies, because of the known phenomenon of publication bias where studies with statistically significant results are more likely to be published than those which show no group difference13. Work in a number of different subject areas has shown that 
Once all potentially relevant studies have been assembled, they should be examined to determine if they fulfil the inclusion criteria for the review. Ideally, this is done independently by at least two reviewers. The trials to be included should then be critically appraised in order to limit bias and to guide interpretation of findings. The validity of a study (the extent to which its design and conduct are likely to prevent systematic errors or bias) should be assessed and there are established methods for doing this'7"18. In preparing a review, investigators collect data from individual RCTs in a similar way to which investigators in a trial collect data from individual patients. These data should then be systematically extracted from each trial report. Important information may be missing or difficult to interpret and contact with the primary investigators is then needed to obtain missing data or to clarify aspects about the conduct of the study.
In a review, as in a primary study, statistical methods, often referred to as meta-analysis, can be used to analyse and summarize data. They can be used to help answer the questions, 'Does this intervention have a beneficial effect' and if so 'What is the size of that effect'. The same questions can be asked about harmful effects. When used appropriately, they provide a powerful tool for deriving meaningful conclusions from the data and help prevent errors in interpretation. If statistical methods are not used to aggregate data in systematic reviews, there is frequently a tendency to vote count, i.e. to compare the number of positive studies with the number of negative studies. With such a vote-counting approach, a study may be counted as positive in one review and negative in another, depending on how the results are interpreted by the reviewers. The simplistic approach of vote counting has many problems, the most obvious of which is that it gives all studies equal weight, ignoring differences in the size and quality of the studies.
A systematic review which does not include metaanalysis may be just as valuable as one which does. Important reasons for not using meta-analysis are (1) if there is a lack of relevant, valid data and (2) if it is inappropriate or misleading to aggregate the data from the individual studies. Like any tool, meta-analysis may be misused and there are a number of well-publicized examples of misleading meta-analysisl9. Recently, a number of studies have compared the results of meta-analyses with those obtained in large clinical trials addressing the same issue20-22, and although there were differences there was surprising agreement between the results23. Meta-analyses can mislead by ignoring important aspects of heterogeneity between studies, reinforcing the bias in individual studies and introducing further biases by using inappropriate means of finding and selecting studies to be pooled22. All of this stresses the importance of attention to rigorous methodology as described in the previous paragraphs. Meta-analysis is simply one of the final steps in a comprehensive and exacting process.
An important attribute of Cochrane reviews is that unlike paper publications, they are regularly updated as new material, relevant to the review, becomes available. This is possible because they are published electronically on The Cochrane Library26 (see below). An individual who undertakes to be the main reviewer needs to take on responsibility for updating it.
THE COCHRANE COLLABORATION
The move towards ensuring clinical effectiveness has been given momentum by the formation of the Cochrane Collaboration at a meeting in Oxford in 1994. The Cochrane Collaboration is an international network of individuals and institutions dedicated to producing systematic reviews of the effects of health care interventions, using mainly RCTs as building blocks for research synthesis. The work of the Cochrane Collaboration has, in an article in the Lancet, been likened in scale and importance to that of the Human Genome Project24. Systematic reviews have been described as secondary research, but in several respects are primary in identifying important research questions. The aim of the Cochrane Collaboration is 'to build up and to maintain a core database of systematic upto-date reviews of RCTs of health care, and to arrange for these reviews to be readily accessible through various electronic media'. It has defined seven key principles to enable it to achieve this aim: * Collaboration * Building on the enthusiasm of individuals * Avoiding duplication of effort * Minimizing bias * Striving for relevance * Promoting access * Ensuring quality Based on what has already been achieved for pregnancy and childbirth25 the Cochrane Collaboration is tackling this ambitious goal.
The Cochrane Collaboration thus consists of a growing number of Collaborative Review Groups (CRGs). CRGs are the primary working entities of the Cochrane Collaboration and are made up of individuals sharing an interest in a particular healthcare problem or type of problem, e.g. stroke, inflammatory bowel disease, depression, anxiety and neurosis, diabetes and epilepsy. At the moment, the combined scopes of CRGs cover almost the entire area of healthcare. The main purpose of a CRG is to prepare and maintain systematic reviews within the remit of their scope. Each CRG has its own international network of collaborators who participate in the Group not only by preparing Cochrane Reviews but also by other activities that help the Group to fulfil its aim such as hand-searching journals. Each CRG is coordinated by an editorial team, responsible for regularly updating and submitting an edited module of protocols, reviews and information about the Group which is published on The Cochrane Library26.
There are currently 13 Cochrane Centres dotted throughout the world. They help to coordinate and support the Collaboration and each has specific responsibilities, for example the Italian Cochrane Centre has undertaken to coordinate the translation of articles in languages other than English. Each Centre is responsible for providing support within a specified geographical area. Fields are Cochrane entities that focus on dimensions of health care other than health problems such as the setting of care (e.g. primary care), the type of consumer (e.g. older people), the type of provider (e.g. nursing) or the type of intervention (e.g. physical therapies). Individuals working in Fields handsearch specialist journals, help to ensure that priorities and perspectives in their field of interest are reflected in the work of CRGs, compile specialist databases, co-ordinate activities with relevant agencies outside the Collaboration and comment on systematic reviews relating to their particular area. Methods Working Groups are entities in the Cochrane Collaboration made up of individuals who are interested in the judgements that lead to selection, appraisal, synthesis, interpretation and dissemination of health care information, such as statistical methods and informatics. Each Methods Working Group is responsible for preparing and maintaining a module that is published in The Cochrane Library and includes a description of the group's scope and activities.
One of the most important groups who will use Cochrane reviews are consumers. In this context a consumer' is either someone who has personal or family experience of the condition under consideration, or who, as a formal representativie of a consumer group, has access to currently 11 reviews in preparation (see Box 1) . Those involved with the group participate in a number of ways, including handsearching, undertaking reviews and peer review of protocols and reviews. Members of the group include clinicians caring for CF adults and children from a number of relevant specialities, physiotherapists, dieticians, nurses and consumers. The core editorial team has two consumers, the review group coordinator and an editor. Consumers are also involved in doing reviews, and as external referees. Information about the group has been published in articles written for consumer organizations in a number of countries including the UK and France. The review group coordinator produces a quarterly newsletter which is sent to participants and is also available on the internet (http:// hiru.mcmaster.ca/cochrane/newslet/cf/default.htm). The group has recently created its own Website (http:// web .bham . ac . uk/walterss/ CFcochranel .htm).
Clearly, the task of performing systematic reviews of all areas of care in CF is a major undertaking. Some have expressed disappointment that the first reviews have not provided clear guidance about, for example, when ursodeoxycholic acid should be used as a preventative treatment and in which patients. Reviews which are unable to demonstrate a clear effect of treatment, or the magnitude of any effect, still perform a vital service. If the primary research is lacking, as it is in many areas of CF care, by clearly demonstrating this, systematic reviews can provide a powerful justification for large, good quality RCTs. So reviews can not only provide the building blocks for clinical guidelines, but can drive a much needed research agenda.
